Caitlin Conboy - Publications

ASO Visual Abstract: The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma.

Journal: Annals of surgical oncology

Published: July 04, 2026

Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma.

Journal: The oncologist

Published: June 11, 2026

Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.

Journal: Journal of gastrointestinal oncology

Published: May 25, 2026

ASO Visual Abstract: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma.

Journal: Annals of surgical oncology

Published: May 07, 2026

Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 25, 2026

Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinoma.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: April 18, 2026

The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma.

Journal: Annals of surgical oncology

Published: April 08, 2026

Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma.

Journal: Annals of surgical oncology

Published: February 25, 2026

Therapeutic targeting of cancer-associated fibroblasts with oncolytic virus in preclinical models of intrahepatic cholangiocarcinoma.

Journal: Molecular therapy. Oncology

Published: February 06, 2026

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma.

Journal: Future oncology (London, England)

Published: July 28, 2025

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.

Journal: The oncologist

Published: June 15, 2025